Established by Professor Shudong Wang in 2017, Aucentra Therapeutics develops breakthrough drugs to address unmet medical needs for some of the most difficult-to-treat cancer.

Prof Wang, Professor of Medicinal Chemistry at the University of South Australia, has over 20-years of cancer drug research and development experience and was previously the former Head of Chemistry at Cyclacel Pharmaceuticals Inc; with decades of experience specialising in the development of CDK inhibitors, Prof Wang is recognised as a global pioneer in this field.  Aucentra’s deep pipeline of proprietary anti-cancer drugs, developed in collaboration with UniSA, include candidates to treat leukaemia, glioblastoma, cancers of colon, pancreas, ovary, breast, and lung. These novel compounds will transform cancer treatment by providing targeted and efficacious medicines with less side effects.

Aucentra’s expertise spans across the entire pharmaceutical lifecycle, encompassing drug discovery, development, and clinical implementation. This comprehensive approach demonstrates a unique, distinctive and efficient business model.